Takeda addressing Gammagard Liquid supplies but says it will take time

Shire Covington, Georgia plant
This $1 billion, 1-million-square-foot plasma fractionation plant in Georgia has gone through four owners already since it was envisioned. It now belongs to Takeda, which has pledged to use it to deal with shortages of the rare disease drugs it produces. (Takeda)

Shire opened a new $1 billion plant in the U.S. in October, and the first product that will come out will be its immune deficiency treatment Gammagard Liquid. But given the long lead time needed to produce and deliver the rare disease drug to the market, a tight supply is projected to continue through this year.

Takeda, which completed its $58 billion buyout of Shire in January, says it is committed to dealing with the shortage. In addition to opening the new plant near Covington, Georgia, it boosted its plasma collections 21% last year and is looking at buying plasma from third parties.

“As a result of the manufacturing time required to produce Gammagard Liquid combined with growing demand, we are experiencing Gammagard Liquid supply tightness that will likely persist throughout 2019,” Takeda said in an email.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

The 1-million-square-foot plant with 850 employees will provide a big boost in supplies, but given it takes 7 to 12 months to manufacture and supply customers with the plasma-derived product, Takeda said that “quick shifts based on demand trends are often not feasible, especially in time of constraints.”

It has taken some years to get the plant open, and it has gone through multiple owners during the process. The facility was announced in 2012 when Baxalta was still the drug unit of Baxter International. Baxter spun the drug unit off into Baxalta in 2014, and Shire bought Baxalta in a $32 billion deal in 2016 in a move to broaden its offerings. The plant ended up as part of Takeda with its buyout of Dublin-based Shire.

The company intends to make a variety of immunoglobulin products there targeted at primary immune deficiency disorders. In March, it received FDA approval to make Flexbumin 25% at the plant. 

Suggested Articles

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.

Merck & Co.'s Fosamax fight has lasted for years—and now, thanks to a U.S. Supreme Court ruling Monday, Merck gets yet another chance to press its…

Mallinckrodt’s Acthar Gel has seen its share of lawsuits, but the company was happy to launch another—this time to defend its Medicaid business.